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CaveolaeTransforming growth factor-β (TGF-β) is implicated in numerous pathological disorders, including cancer and
mediates a broad range of biological responses by signaling through the type I and II TGF-β receptors.
Internalization of these receptors via the clathrin-coated pits pathway facilitates SMAD-mediated signaling,
whereas internalization via the caveolae pathway is associated with receptor degradation. Thus, molecules that
modulate receptor endocytosis are likely to play a critical role in regulating TGF-β action.Wepreviously identiﬁed
CD109, a GPI-anchored protein, as a TGF-β co-receptor and a negative regulator of TGF-β signaling. Here, we
demonstrate that CD109 associates with caveolin-1, a major component of the caveolae. Moreover, CD109
increases binding of TGF-β to its receptors and enhances their internalization via the caveolae. In addition, CD109
promotes localization of the TGF-β receptors into the caveolar compartment in the presence of ligand and
facilitates TGF-β-receptor degradation. Thus, CD109 regulates TGF-β receptor endocytosis and degradation to
inhibit TGF-β signaling.; Smurf, SMAD ubiquitination
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TGF-β5, a multifunctional growth factor with three different
subtypes, TGF-β1, β2, β3, controls numerous cellular processes such
as growth, differentiation, migration and extracellular matrix depo-
sition, and thus plays a crucial role in development and homeostasis
[1]. Dysregulation of its signaling pathway has been implicated in
tissue ﬁbrosis and cancer, underscoring the critical importance of a
tight regulation of TGF-β action.
TGF-β signaling is transduced by a pair of transmembrane serine/
threoninekinasesknownas type I (TGFBR1)and II (TGFBR2) receptors [2].
The binding of TGF-β to TGFBR2, a constitutively active kinase, results in
the phosphorylation of TGFBR1. The activated TGFBR1 then propagates
the signal by phosphorylating its intracellular substrates SMAD2 and
SMAD3, which in turn form complexes with SMAD4. The complexes
accumulate in the nucleus, where they regulate gene expression [3].In addition to the type I and II receptors, many cell types also
express the TGF-β co-receptors betaglycan and endoglin [4]. Our
group has recently identiﬁed another TGF-β co-receptor, CD109, in
skin cells [5]. CD109 is a 180 kDa glycosylphosphatidylinositol (GPI)-
anchored protein that belongs to the α2-macroglobulin/complement
family [6]. CD109 binds the TGF-β1 subtype with high afﬁnity, forms a
heteromeric complex with the TGF-β signaling receptors and inhibits
TGF-β signaling and responses in a variety of cell types [5]. Moreover,
recent reports have shown that CD109 expression is deregulated in
basal-like breast carcinoma [7], squamous cell carcinoma [8–11] and
melanoma [5] and that CD109 is mutated in colorectal cancer [12].
Despite its important role in TGF-β signaling and its potential
signiﬁcance in cancer progression, its mechanism of action is not yet
understood.
Receptor endocytosis is a pivotal regulatory mechanism in signal
transduction. TGF-β receptors are internalized via both clathrin- and
caveolae-dependent pathways [13]. Internalization of the TGF-β
receptors via the clathrin-coated pits has been linked with signaling
via SMAD2/3 and receptor recycling [14–17]. In contrast, TGF-β
receptor localization in caveolae is associated with downregulation of
SMAD2/3 signaling and receptor degradation following ubiquitination
by the E3-ubiquitin ligase Smurf2 [13,18].
Because CD109 is a negative regulator of TGF-β signaling, we
investigated whether CD109 exerts this effect by modulating
caveolae-mediated internalization of the TGF-β receptors or
receptor degradation.
743A.A. Bizet et al. / Biochimica et Biophysica Acta 1813 (2011) 742–7532. Materials and methods
2.1. Cell lines
The human keratinocyte cell line HaCaT, kindly provided by P.
Boukamp (Heidelberg, Germany), Mv1Lu cells and human embryonic
kidney 293 cells purchased from the American Type Culture Collection,
were cultured as described previously [5]. HaCaT clones stably
expressing CD109 (or its empty vector, EV) were selected and cultured
in the presence of 0.5 mg/ml Geneticin (Invitrogen, Carlsbad, CA, USA).2.2. Transient transfections and siRNA treatment
Transfections of different combinations of the following plasmids:
CD109 or its empty vector (pCMVSport6), caveolin-1 (gift from C.
Hardin, University of Missouri), Dyn2K44A (gift from S. Egan,
University of Toronto), TGFBR2 and TGFBR1-WT (gifts from J. Wrana,
University of Toronto) were performed using Superfect (Qiagen,
Mississauga, ON, Canada). Alternatively, cells were transfected with
CD109 siRNA (cat.#129083), caveolin-1 siRNA (cat.#10297) or a
negative control siRNA (cat.#4611) (Ambion, Austin, TX, USA) using
Lipofectamine 2000 (Invitrogen).2.3. Afﬁnity labeling
293 cells or HaCaT cells were incubated with 100 pM
125
I-TGF-β1
for 3 h at 4 °C, the ligandwas cross-linked to the receptors with a non-
permeable cross-linker BS3 (Pierce, Rockford, IL) and the cells were
incubated at 37 °C for 0 to 8 h prior to lysis as previously described
[19]. Protein concentrations were determined using a Lowry protein
assay (Bio-Rad, Mississauga, ON, Canada) and the lysates were
analyzed by SDS-PAGE/autoradiography. Densitometry was per-
formed using the ImageJ software.2.4. Immunoprecipitation and western blot
Lysates from 293 cells were immunoprecipitated with a mouse
monoclonal anti-caveolin-1 antibody (clone 2297, BD Biosciences,
Mississauga, ON, Canada). Lysates from HaCaT cells were immuno-
precipitated with mouse monoclonal anti-CD109 (gift from R&D
systems, Minneapolis, MN, USA) or a rabbit polyclonal anti-caveolin-1
antibody (BD Biosciences), while a mouse monoclonal anti-histone
H1 or a rabbit polyclonal anti-HA antibodies (both from Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were used as control IgG.
Western blot analyses were conducted with the following antibodies:
mouse monoclonal anti-CD109 (TEA 2/16, BD Biosciences), anti-EEA-
1(BD Biosciences), anti-SMAD3 (FL-425) and anti-actin (H-300)
antibodies (both form Santa Cruz Biotechnology), rabbit polyclonal
anti-TGFBR1 and anti-phospho-SMAD3 antibodies (both from Cell
Signaling Technologies, Danvers, MA, USA).2.5. Internalization assay
Internalization assay was performed as described in Ref.
[20] with some modiﬁcations. Brieﬂy, cells were treated with
2.5 mM MβCD (Sigma Aldrich, Oakville, ON, Canada) for 1 h at 37 °C
prior to internalization assay. Cells were then incubated with
100 pM
125
I-TGF-β1 (Perkin Elmer, Waltham, MA, USA) with or
without 10 nM unlabeled TGF-β1 (to determine non-speciﬁc binding)
for 2 h at 4 °C and transferred to 37 °C for the indicated time.
Surface ligand was removed with 150 mM NaCl, 0.1% acetic acid, 2 M
urea. Cells were then solubilized in order to extract internalized
ligand.2.6. Sucrose gradient fractionation
Preparation of membrane fraction from HaCaT cells was per-
formed as described in Ref. [21]. The twelve fractions collected were
analyzed by western blot for EEA-1 and caveolin-1. The fractions
containing EEA-1 or caveolin-1 were pooled and equal amounts
of protein were analyzed by SDS-PAGE/autoradiography or western
blot.
2.7. Immunoﬂuorescence microscopy
293 cells were incubated with 250 pM biotinylated-TGF-β1 (R&D,
Minneapolis, MN, USA) for 2 h at 4 °C, then with 10 μg/ml streptavi-
din-AF647 for 1 h at 4 °C and placed at 37 °C in DMEM, 10% FBS, for
30 min. Cells were ﬁxed with 4% paraformaldehyde and permeabi-
lized with methanol. After blocking non-speciﬁc sites with 10%
normal goat serum, cells were stained using an anti-CD109 antibody
followed by an Alexa Fluor 488 (AF488) conjugated anti-mouse IgG
(Invitrogen) or by a Cy5-conjugated Fab fragment goat anti-mouse
IgG (Jackson ImmunoResearch Lab, West Grove, PA, USA). Cells were
then stained with a Cy3 conjugated rabbit anti-caveolin-1 or AF488
conjugated mouse anti-HA antibodies (Invitrogen). Images were
acquired with a LSM 510 META Axioplan 2 confocal laser scanning
microscope (Carl Zeiss, Toronto, ON, Canada) as described previously
[22]. Background was removed by median ﬁltering [23] or by
deconvolution using Huygens Professional Software (Fig. 1D and
Supplementary Fig. S2D).
2.8. Plasma membrane preparation
Cell surface proteins were extracted using the Hook Cell Surface
Protein Isolation kit (G-Biosciences, St. Louis, MO, USA). Brieﬂy, cell
surface proteins were labeled with Hook-sulfo-NHS-SS-Biotin and
lysed. An aliquot was analyzed by western blot for actin to make sure
that equal amount of protein was used. Biotinylated proteins from the
remaining lysates were isolated using streptavidin-agarose column,
eluted and analyzed by western blot.
2.9. Statistical methods
Numerical results are represented as means of n≥3 independent
experiments±SEM. Statistical signiﬁcance between two groups was
determined by two-tailed Student t test. Comparisons within more
than two groups weremade by one-way analysis of variance. Multiple
comparisons were made by Holm–Sidak test (post-hoc).
3. Results
3.1. CD109 associates with caveolin-1 at endogenous concentration
We sought to determine whether CD109 exerts its negative effects
on TGF-β signaling bymodulating TGF-β receptor localization into the
caveolae, a process shown to enhance TGF-β receptor degradation.We
ﬁrst examined whether CD109, a GPI-anchored protein, can associate
with caveolin-1, a major component of the caveolae. Co-immunopre-
cipitation experiments reveal that CD109 associateswith caveolin-1 in
293 cells co-transfected with both CD109 and caveolin-1 (Fig. 1A). In
the absence of caveolin-1 transfection, (i.e. when caveolin-1 expres-
sion is undetectable [24]), CD109 is not co-immunoprecipitated
(Fig. 1A), demonstrating the speciﬁcity of the association.
In untransfected HaCaT cells, caveolin-1 is co-immunoprecipitated
by an anti-CD109 antibody (Fig. 1B), conﬁrming that the interaction
between CD109 and caveolin-1 is not an artifact of overexpression
and that it occurs at endogenous concentrations of caveolin-1 and
CD109 (Fig. 1B). Similarly, an anti-caveolin-1 antibody co-immuno-
precipitates small but detectable amounts of CD109 (Supplementary
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caveolin-1 is enhanced after TGF-β treatment (Fig. 1C).
Immunoﬂuorescence microscopy of HaCaT cells (Fig. 1D) shows
that caveolin-1 (in red) displays a punctate staining pattern at the
plasma membrane, with some punctate staining in the cytoplasm,
which may represent neo-synthesized or internalized caveolin-1.
Endogenous CD109 (blue) localizes mainly at the plasma membrane
in both non-caveolar and caveolin-1 positive compartments. The
colocalization of CD109 with caveolin-1 (in purple, Fig. 1D) suggests
that CD109 is able to associate with caveolin-1 in the same cellular
compartment, supporting the results obtained in Fig. 1A–C.3.2. CD109 and TGF-β receptors colocalize in caveolae
We have previously shown that CD109 binds directly to TGFBR1 [5].
We therefore sought to determine whether TGF-β receptors co-localize
with CD109 in caveolae. Because the endogenous levels of TGF-β
receptors in HaCaT cells are too low to allow detection of the
internalized ligand, 293 cells were transfected with TGFBR1/TGFBR2
and caveolin-1 and labeledwith biotin-TGF-β, followed by streptavidin-
AF647 treatment. After 30 min at 37 °C to allow receptor and ligand
internalization, the cellswere immunostained for CD109 and caveolin-1
(Fig. 1E). Importantly, a signiﬁcant amount of triple colocalization
(visualized in white) is observed between the internalized biotin-TGF-β
(in green), CD109 (in blue), and caveolin-1(in red) (Fig. 1E). The
proportion of internalized biotin-TGF-β that is not associated with
CD109 and caveolin-1 (Fig. 1E) may represent molecules that are
internalized via the clathrin pathway (associated with SMAD2/3
signaling) or that are in recycling compartments. In the absence of
TGF-β treatment, CD109 localizes mainly at the plasma membrane,
where it partially co-localizes with caveolin-1 (Fig. 1F), as observed in
untransfected HaCaT cells (Fig. 1D). When the cells were incubated at
4 °C instead of 37 °C, no biotin-TGF-β staining was detected (data not
shown), indicating that at 4 °C, the receptors are not internalized.
Interestingly, in the absence of TGF-β receptor transfection, low levels of
co-localization between CD109 and caveolin-1 could be observed
(Fig. 1G and Supplementary Fig. S2A). It is possible that the interaction
between the GPI-anchored CD109 and the integral membrane protein
caveolin-1 is mediated via endogenous TGF-β receptors in that case,
although the contribution of other transmembrane proteins or lipid
molecules cannot be ruled out.
The notion that the biotin-TGF-β staining is speciﬁc for biotin-TGF-
β bound to TGFBR1/TGFBR2 complex and not to other TGF-β binding
molecules under our detection settings is supported by the following
results: (1) when TGFBR1/TGFBR2 are not transfected, no staining is
observed for biotin-TGF-β, even in the presence of CD109 (Fig. 1G);
(2) biotin-TGF-β colocalizes with HA-tagged TGFBR1 (Supplementary
Fig. S2C). This suggests that TGF-β follows the same internalization
route as TGFBR1, as reported by others [13,20]; (3) HA-TGFBR1 co-
localizes with CD109 in caveolae vesicles and at the plasma
membrane (Supplementary Fig. S2D). Together, these data indicate
that biotin-TGF-β can be used to assess TGF-β receptor localization
and suggest that CD109 is able to form a complex with TGF-β-bound
TGF-β receptors (activated receptors) in caveolae.Fig. 1. CD109 associates with caveolin-1 and colocalizes with the TGF-β receptors in caveola
and caveolin-1 or their corresponding empty vector were immunoprecipitated with an anti-
IgG band demonstrates equal loading. (B) Cell lysates from non-transfected HaCaT cells we
(used as control IgG), followed by western blot for CD109 and caveolin-1. (C) Non-transfect
then subjected to immunoprecipitation with an anti-caveolin-1 antibody or with an anti-HA
densitometry of CD109 levels in the immunoprecipitate is indicated. (D–G) Immunoﬂuor
endogenous CD109 (blue). Co-localization of CD109 with caveolin-1 appears in purple. (E) 2
TGF-β/streptavidin (green) and incubated for 30 min at 37 °C to allow receptor internalizatio
confocal microscopy. Triple co-localization of caveolin-1, CD109, and biotin-TGF-β appears i
transfected as in (E) were left untreated and stained for CD109 (blue) and caveolin-1 (red). C
experiments is shown. (G) 293 cells transfected with CD109, caveolin-1, TGFBR1/TGFBR2 o
where colocalization between CD109 and caveolin-1 occurs. A representative panel of cells3.3. CD109 enhances binding of TGF-β to TGF-β receptors and TGF-β-bound
receptor internalization
We then asked if CD109 affects TGF-β-bound receptor internaliza-
tion. CD109 overexpression signiﬁcantly (pb0.05, n=5 independent
experiments) increases the number of cells that have internalized
biotin-TGF-β (i.e. TGF-β-bound receptors) as compared to empty vector
(EV) transfection in 293 cells (Fig. 2A and B). After normalization for
transfection efﬁciency (as determined by caveolin-1 expression), we
observe that 64% of caveolin-1 positive cells internalize biotin-TGF-β in
the presence of CD109, whereas only 27% incorporate biotin-TGF-β in
EV transfected cells (Fig. 2B), suggesting that CD109 increases the
internalization of TGF-β-bound receptors. The amount of internalized
biotin-TGF-β reﬂects the levels of receptors that underwent endocyto-
sis, and also any recycling and/or degradation that may have occurred
during that time period. Notably, CD109 transfection does not alter the
level of TGF-β receptors or caveolin-1, as compared to EV transfection
(Fig. 3B and data not shown), suggesting that CD109 only affects the
amount of internalized TGF-β-bound receptors.
We next examined the effect of CD109 on the internalization of
125
I-TGF-β at endogenous TGF-β receptor concentration in HaCaT cells.
The
125
I-TGF-β internalization assay has been shown to reliably reﬂect
receptor internalization [20,25]. At early time points (15 and 30 min),
CD109 enhances
125
I-TGF-β internalization (Fig. 2C). The increase of
125
I-TGF-β internalization in CD109 overexpressing cells is followed by a
decline after 30 min whereas a decline occurs only after 60 min in EV
transfected cells (Fig. 2C). Thedecline in internalized
125
I-TGF-βhas been
reported previously and might be due to ligand depletion and/or
degradation [20]. Importantly, our results suggest that CD109 enhances
ligand-bound receptor internalization.
Interestingly, CD109 overexpression is associated not only with an
increase of
125
I-TGF-β internalization, but also with an increase of
surface-bound
125
I-TGF-β at 30 min (Fig. 2D). The ratio of internalized/
surface-bound
125
I-TGF-β (I/S) is higher in CD109 transfected cells, as
compared to EV cells at both 15 and 30 min (Fig. 2E), suggesting that
CD109 accelerates TGF-β-bound receptor endocytosis. Moreover,
knocking down CD109 expression using CD109 siRNA or CD109
antisense morpholino oligos leads to a decrease in both internalized
and surface-bound
125
I-TGF-β at 30 min (Fig. 2F and Supplementary
Fig. S3). These results indicate that endogenous CD109 increases surface
binding and internalization of TGF-β.
To determine whether the increase in TGF-β binding to the cell
surface is due to an increase in TGF-βbinding to theTGF-β receptors and
not solely due to an increase in TGF-β binding to CD109, we performed
afﬁnity labeling of cell surface receptors at 4 °C followed by SDS-PAGE
analysis. Our results show that CD109 is able to enhance TGF-β binding
to the receptors (Fig. 3A and B). CD109 siRNA transfection inHaCaT cells
decreases and CD109 overexpression in 293 cells increases the amount
of cell surface
125
I-TGF-β-bound receptors (Fig. 3A and B). Notably,
CD109 does not affect the total level of TGFBR1, as demonstrated by
western blot (Fig. 3A and B). Moreover, overexpression of CD109 does
not alter the cell-surface level of TGF-β receptors (Fig. 3B). These results,
together with our previous ﬁndings demonstrating that CD109 forms a
complexwith the TGF-β receptors [5], suggest that suchassociation is an
important step in CD109's ability to increase TGF-β binding to thise. (A–C) Co-immunoprecipitation: (A) Cell lysates from 293 cells transfected with CD109
caveolin-1 (cav-1) antibody followed by western blot with an anti-CD109 antibody. The
re immunoprecipitated with an anti-CD109 antibody or with an anti-histone antibody
ed HaCaT cells were treated with or without 25 pM TGF-β for 30 min. Cell lysates were
antibody (used as control IgG), followed by western blot for CD109 and caveolin-1. The
escence: (D) HaCaT cells were immunostained for endogenous caveolin-1 (red) and
93 cells transfected with CD109, caveolin-1, TGFBR1/TGFBR2 were stained with biotin-
n. After ﬁxation, cells were stained for CD109 (blue) and caveolin (red) and analyzed by
n white. A representative cell of n=5 independent experiments is shown. (F) 293 cells
o-localization of CD109 with caveolin-1 appears in purple. A representative cell of n=3
r their corresponding empty vectors were stained as in (E). The arrow points at a cell
is shown (n=3 experiments)
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this TGF-β bound-complex.
3.4. CD109 enhances TGF-β receptor internalization via the caveolar
pathway
Next, we assessed if the CD109-induced increase in TGF-β receptor
internalization could be mediated by the caveolar compartment.Internalization of biotin-TGF-β in EV transfected 293 cells is
prevented by co-transfection of the Dynamin2-K44A mutant
(Dyn2K44A) (Fig. 4A), which blocks endocytosis via both clathrin
and caveolar pathways [26] and is consistent with previous reports
demonstrating that TGF-β receptors are internalized via clathrin and/
or caveolae pathways [13,27]. Importantly, internalization of biotin-
TGF-β is also blocked by co-transfection of the Dynamin2-K44A
mutant (Dyn2K44A) when CD109 is overexpressed (Fig. 4A). In the
Fig. 2. CD109 promotes TGF-β internalization. (A–B) Immunoﬂuorescence: 293 cells were stained with biotin-TGF-β/streptavidin (green) and incubated for 30 min at 37 °C to allow
receptor internalization. Cells were ﬁxed and immunostained for CD109 (blue) and caveolin (red) and analyzed by confocal microscopy. (A) Comparison of populations of CD109 and
control empty vector (EV) transfected cells. A representative cell showing internalization of biotin-TGF-β is enlarged in the left corner of the overlay. (B) Percentage of transfected
(caveolin-1 positive) cells that have internalized biotin-TGF-β (mean of n=5 independent experiments±SEM, *: pb0.05). (C–F)
125
I-TGF-β internalization assay: (C) Left panel:
HaCaT cells transfected with CD109 or EVwere treated with 100 pM
125
I-TGF-β and incubated at 37 °C for the indicated times. The graph shows the amount of internalized
125
I-TGF-β1
(expressed as speciﬁc cpm). Right panel: Western blot showing CD109 overexpression in HaCaT cells. (D) Amount of surface-bound and internalized
125
I-TGF-β after 30 min
incubation at 37 °C in HaCaT cells transfected with CD109 or EV (normalized to surface-bound EV). (E) Ratio of internalized/surface-bound
125
I-TGF-β (I/S) in HaCaT cells transfected
with CD109 or EV. (F) Left panel: Amount of surface-bound and internalized
125
I-TGF-β after 30 min incubation at 37 °C in HaCaT cells transfected with CD109 siRNA or control siRNA
(normalized to surface-bound control siRNA). Right panel: Western blot showing CD109 siRNA efﬁcacy. All graphs show the mean of nN3 independent experiments, ± SEM,
*: pb0.05.
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plasma membrane in 81 (± 5.2)% of the cells and co-localizes with
CD109 staining, whereas the biotin-TGF-β staining is found at the
plasma membrane in only 5.1 (± 4.6)% of the cells in the absence of
Dyn2K44A (Fig. 4A). This indicates that CD109 promotes dynamin-
dependent internalization of the TGF-β-bound receptors.
Because CD109 is an inhibitor of TGF-β signaling [5], we looked
more speciﬁcally at CD109's ability to increase internalization viacaveolae, a route that has been shown to lead to receptor degradation
and signaling downregulation. We demonstrate that pre-treatment
with methyl-β-cyclodextrin (MβCD), an inhibitor of the caveolae/
lipid raft-dependent endocytosis [17,26] blocks CD109's effect on
125
I-TGF-β internalization in HaCaT cells (Fig. 4B). The increase in
TGF-β internalization mediated by CD109 is also reversed by
caveolin-1 siRNA (Fig. 4C), conﬁrming that CD109 is able to enhance
caveolae-mediated endocytosis. The slight (and non-signiﬁcant)
Fig. 3. CD109 enhances TGF-β binding to the TGF-β receptors without altering the total or cell surface receptor levels. (A) HaCaT cells transfected with control or CD109 siRNA were
afﬁnity labeled with 100 pM
125
I-TGF-β. Left panel: The amount of cell surface receptors bound to TGF-β is visualized by autoradiography. CD109 is detected as two bands of 180 and
150 kDa, as described previously [5]. Right panel: The same lysates were analyzed for TGFBR1 by western blot. (B) 293 cells transfected with TGFBR1, TGFBR2 and CD109 or its control
EV were afﬁnity labeled with 100 pM
125
I-TGF-β. Left panel: Autoradiography showing the amount of cell surface TGF-β-bound receptors. Middle panel: The same lysates were
analyzed for TGFBR1 by western blot. Right panel: Cell surface proteins from 293 cells transfected with TGFBR1/TGFBR2, CD109 or EV were labeled with Hook-sulfo-NHS-SS-Biotin,
pulled down with streptavidin and analyzed by western blot with CD109 and TGFBR1 antibodies. Similar amounts of protein were used in the experiment as demonstrated by the
actin blot. All results are representative of n=3 independent experiments and all lanes from a panel come from the same blot.
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transfection in EV transfected cells suggests that the internalization
of TGF-β via the caveolar pathway at basal conditions is modest in
HaCaT cells. This is not consistent with the report showing that
about 50% of TGF-β receptors localized in caveolae in Mv1Lu cells
[13]. To determine whether the discrepancy is due to cell-type
speciﬁc differences, we determined whether CD109 regulates TGF-β
internalization into caveolae in Mv1Lu cells. In this cell type, CD109
siRNA decreases
125
I-TGF-β internalization as expected, in the
absence of MβCD (Fig. 4D). Importantly, treatment of MβCD leads
to a reduction of
125
I-TGF-β internalization in control siRNA but not in
CD109 siRNA transfected cells, indicating that, in Mv1Lu cells, a large
proportion of TGF-β is internalized via the caveolae and that
endogenous CD109 mediates this effect. In addition, these results
support the argument that the amount of TGF-β internalizing via the
caveolae varies between cell-types. Also, the difference observed in
control siRNAMv1Lu or EV HaCaT cells in presence of MβCD is due to
cell type speciﬁcity since no difference was observed between EV
and control siRNA transfection in the absence of MβCD (data not
shown). Together, our results suggest that CD109 increases the
proportion of TGF-β-bound receptors that internalize via the caveolar
pathway.
3.5. CD109 promotes TGFBR1 compartmentalization into the caveolae in
a ligand-dependent manner
TGF-β receptors have been shown to trafﬁc independently of
ligand addition [13,17]. Thus, we determined whether the effect ofCD109 on TGFBR1 trafﬁcking occurs in a ligand-independent manner.
By sucrose gradient centrifugation, the raft fractions (fractions 5 and
6) were separated from the non-raft fractions (fractions 8 to 12). The
purity of the raft and the non-raft fraction was veriﬁed using the early
endosome antigen-1 (EEA-1) and caveolin-1, two markers conven-
tionally used for the non-raft/endosomal and the raft/caveolar
compartment, respectively [13,21] (Fig. 5A). The analysis of TGFBR1
and CD109 localization in the pooled raft and pooled non-raft
fractions were performed on the same gel by western blot (Fig. 5B).
In the absence of exogenous TGF-β, TGFBR1 is present predominantly
in the non-raft fraction in both CD109 and EV transfected cells. In
contrast, TGF-β treatment leads to a marked increase in the amount of
TGFBR1 in the raft fraction of CD109 transfected cells as compared
to EV transfected cells (Fig. 5B). In addition, TGF-β treatment of
EV transfected cells results in a modest increase in the amount of
TGFBR1 in the raft fraction (Fig. 5B), presumably due to the presence
of endogenous CD109. The low amount of TGFBR1 detected in the
raft fraction in HaCaT cells is consistent with our previous results in
this cell type (Fig. 4B) showing that only a small amount of TGF-β-
bound receptors is internalized via the lipid raft/caveolar pathway
in EV transfected HaCaT cells. Under basal conditions, CD109
localizes mainly in the non-raft compartment, but is also present in
the lipid raft compartment (visualized on amore exposed ﬁlm), which
agrees with our immunoﬂuorescence data (Fig. 1D). The effect of TGF-
β on the pattern of CD109 localization is similar to the one observed for
TGFBR1: TGF-β treatment increases the localization of CD109 in the raft
compartment, which is consistent with our co-immunoprecipitation
data (Fig. 1C). Together, these results suggest that CD109 promotes
Fig. 4. CD109 enhances TGF-β internalization via the caveolar pathway. (A) Immunoﬂuorescence: 293 cells transfected with TGFBR1/TGFBR2, CD109 (or its EV) and Dyn2K44A (or its
EV) were treated with biotin-TGF-β/streptavidin (green), incubated for 30 min at 37 °C and stained for CD109 (blue). Colocalization of CD109 and biotin-TGF-β appears in turquoise
(overlay). Representative cells are shown. (B–D)
125
I-TGF-β internalization assay: (B) HaCaT cells transfected with CD109 or EVwere treated with or without MβCD prior to incubation
with
125
I-TGF-β. The graph shows the amounts of internalized
125
I-TGF-β after 30 min incubation at 37 °C (normalized to EV, no treatment). (C) Left panel: Amount of internalized
125
I-
TGF-β after 30 min incubation at 37 °C in HaCaT cells co-transfected with CD109 or EV and with caveolin-1 or control siRNA (normalized to EV, control siRNA). Right panel: Western
blot showing caveolin-1 siRNA efﬁcacy. (D) Left panel: Mv1Lu cells transfected with CD109 siRNA or control siRNA were treated with or without MβCD prior to incubation with
125
I-
TGF-β. The graph shows the amounts of internalized
125
I-TGF-β after 30 min incubation at 37 °C (normalized to CD109 siRNA, no treatment). Right panel: Western blot showing
CD109 siRNA efﬁcacy in Mv1Lu cells. All graphs show the mean of n≥3 independent experiments±SEM, *: pb0.05.
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treatment.
We further examined the ability of CD109 to induce TGF-β-bound
receptor localization to the caveolar compartment by ﬁrst afﬁnity
labeling the receptors on HaCaT cells with
125
I-TGF-β and then
performing sucrose gradient fractionation as describe above. In
CD109 transfected cells, the majority of TGF-β-bound TGFBR1
localizes into the caveolin-1 positive/lipid raft fraction, whereas in
EV transfectants, TGFBR1 resides mainly in the non-raft fraction
(Fig. 5C). Similar results were obtained with TGF-β-bound TGFBR2
(data not shown). These results indicate that CD109 leads to
preferential localization of TGFBR1 into the lipid raft compartment,
in the presence of TGF-β.3.6. Inhibition of TGF-β signaling by CD109 involves caveolae-mediated
internalization
The results presented so far show that CD109 promotes TGF-β
receptor internalization via the caveolae. We next investigated if this
step is involved in mediating CD109's inhibitory effect on TGF-β
signaling. Our results show that overexpression of CD109 inhibits
TGF-β-induced SMAD3 phosphorylation (Fig. 6A), as expected [5].
This inhibitory effect of CD109 is abrogated by co-transfection of
caveolin-1 siRNA (Fig. 6A), indicating that CD109' effects on TGF-β
signaling involve the caveolar pathway. Similarly, knocking down
CD109 expression using siRNA results in an increase in TGF-β-induced
SMAD3 phosphorylation, and this effect is blocked by co-transfection
Fig. 5. CD109 promotes TGFBR1 entry into the caveolar compartment in the presence of TGF-β. (A) Lysates fromHaCaT cells transfectedwith CD109 or EV and treated without (−) or
with (+) 25 pM TGF-β for 30 min were subjected to sucrose gradient fractionation. The resulting fractions were analyzed by western blot for EEA1 and caveolin-1. (B) Left panel: The
pooled raft (fractions 5–6) and pooled non-raft (fractions 8–12) fractions were analyzed by western blot for CD109 and TGFBR1. A representative western blot is shown. Right panel:
Densitometric analysis of TGFBR1 levels. (C) Left panel: HaCaT cells transfected with CD109 or EV were afﬁnity labeled with
125
I-TGF-β prior sucrose gradient fractionation. Labeled
TGFBR1 is detected by autoradiography. Coomassie blue staining shows equal protein loading. The same samples were analyzed for EEA-1 and caveolin-1 by western blot. Right
panel: Densitometric analysis of the autoradiogram.
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of TGF-β signaling by endogenous CD109 involves the caveolar
pathway.
3.7. CD109 accelerates TGF-β receptor degradation
Localization of TGF-β receptors to caveolae has been shown to be
associated not only with a decrease in SMAD2/3 phosphorylation but
also with receptor degradation [13]. Therefore, we tested if CD109
modulates TGF-β receptor degradation, by monitoring the levels of
afﬁnity labeled receptors (Fig. 7A). Consistent with our previous
ﬁndings, CD109 overexpression increases the binding of
125
I-TGF-β to
its receptors, compared to EV transfection (see time 0). TGFBR1,
TGFBR2 and CD109 levels decrease over time, suggesting that the
CD109-TGF-β-bound-receptor complex is being degraded (Fig. 7A).
Quantiﬁcation of TGFBR1 levels by densitometry (expressed as a
percentage of time 0) reveals that CD109 accelerates degradation of
TGF-β-bound receptor (Fig. 7A, right panel, pb0.05). In addition,
stable transfection of CD109 in HaCaT cells (clone CD3-3 and CD2-4)
accelerates the degradation of endogenous TGFBR1 and TGFBR2, as
compared to stable transfection of EV (clone EV3-3 and EV1-6)
(Fig. 7B and Supplementary Fig. S4, pb0.05). Furthermore, the
increased rate of degradation is prevented by MG132, a proteasomeinhibitor, indicating that CD109 enhances proteasomal degradation of
TGF-β receptors (Fig. 7B). Moreover, HaCaT cells transfected with
CD109 siRNA and treated with TGF-β display a signiﬁcant (pb0.05)
increase in TGFBR1 levels, as compared to control siRNA transfection
and this effect of CD109 can be blocked by addition of MG132, but not
chloroquine, an inhibitor of lysosomal degradation (Fig. 7C). These
results indicate that endogenous CD109 facilitates proteasomal
degradation of TGF-β receptors and conﬁrm that the previous results
(Fig. 7A and B) were not an artifact due to CD109 overexpression.
Collectively, our results suggest that CD109 negatively regulates
TGF-β action by promoting TGF-β receptor internalization to the
caveolar compartment and by enhancing TGFBR1 degradation via the
proteasomal pathway (Fig. 8).
4. Discussion
Our group has previously identiﬁed CD109, a GPI-anchored
protein, as a novel TGF-β co-receptor [5]. CD109 has high afﬁnity
for TGF-β1, forms a complex with the TGF-β signaling receptors and
negatively regulates TGF-β signaling in vitro [5]. Mutation of CD109 or
deregulation of its expression has been reported in many cancers [7–
12,28]. Because of CD109's potential relevance as a regulator of TGF-β
action in vivo, we examined themechanism bywhich it regulates TGF-
Fig. 6. CD109's inhibition of TGF-β signaling involves the caveolar pathway. (A–B) Western blot: (A) HaCaT cells transfected with CD109 or its EV, and, caveolin-1 siRNA or control
siRNA were treated with 15 pM TGF-β. Cell lysates were analyzed by western blot for phosphorylated-SMAD3 (P-SMAD3) and total SMAD3 (T-SMAD3). Bottom panel: Densitometry
of P-SMAD3 after 30 min TGF-β treatment (mean of n=4 independent experiments±SEM, *pb0.05). (B) HaCaT cells transfected with CD109 siRNA, caveolin-1 siRNA or control
siRNA were treated with 15 pM TGF-β for 15 min. Cell lysates were analyzed by western blot as in (A). Bottom panel: Densitometry of P-SMAD3 (mean of n=4 independent
experiments±SEM, *pb0.05).
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receptors, promotes TGF-β receptor compartmentalization and
internalization into the caveolae and accelerates TGF-β receptor
proteasomal degradation. Together, these ﬁndings suggest that
downregulation of TGF-β signaling by CD109 involves these mech-
anisms (Fig. 8). In addition, our results suggest that ligand addition
may regulate CD109's effect on TGF-β receptor localization to lipid
raft/caveolar compartment.
Caveolae serve as platforms for signaling molecule assembly,
endocytosis of receptors, and modulation of signaling [29]. They are a
subset of lipid rafts characterized by the insertion of caveolin-1 in the
membrane bilayer and are enriched in GPI-anchored proteins. Here,
we report that caveolin-1 associates with CD109, suggesting that
CD109 can localize to caveolae. This association is likely indirect and
may involve lipid molecules or transmembrane proteins, such as
TGFBR1, which has been shown to interact directly with both CD109
[5] and caveolin-1 [18]. Interestingly, immunoﬂuorescence and
sucrose gradient analyses reveal that CD109 is present in both
caveolar and non-caveolar compartments. Whether the non-caveolar
compartment represents a storage area for CD109 or whether CD109
has other roles in that compartment is not known.
The ability of CD109 to enhance the binding of TGF-β to its
receptors on one hand and to inhibit TGF-β signaling on the other
suggests that CD109 may direct the ligand and its receptors into a
compartment where they cannot signal. Although our results do not
rule out the possibility that CD109 may also play a role in clathrin-
mediated endocytosis of TGF-β receptor, our data showing that
inhibitors of caveolae-mediated endocytosis reverse CD109's effect on
TGF-β internalization suggest that CD109 facilitates TGF-β-bound
receptor internalization via the caveolae, a compartment associated
with TGF-β receptor degradation and signaling downregulation
[13,18]. Accumulation of receptors in caveolae has been shown to
trigger the rapid internalization via caveolae [30]. Thus, CD109 may
facilitate receptor clustering in the presence of ligand to promote their
internalization via the caveolar route. Together, our study demon-
strates that activated TGF-β receptors can internalize via the caveolaeand that this event is regulated by CD109. Thus, an alteration in CD109
concentration, as seen in many cancers, may lead to a change in the
proportion of TGF-β receptor internalizing via caveolae, resulting in
aberrant TGF-β signaling and action.
Several molecules have been implicated in the regulation of TGF-β
receptor compartmentalization. Hyaluronan has been shown to
modulate TGF-β receptor partitioning to caveolae [21], but the
question of hyaluronan controlling TGF-β receptor degradation
remains open. The TGF-β co-receptors betaglycan and its homologue
endoglin have been shown to facilitate TGF-β receptor endocytosis
through their interaction with β-arrestin2, a component of the
clathrin-coated pits [31,32]. However, there is a discrepancy in the
results reported, since internalization via the clathrin pathway leads
to inhibition of TGF-β signaling in one study [31], and delay in
receptor degradation in another study [33]. The proportion of TGF-β
receptors that internalize via the caveolae may vary depending on the
cell type (possibly due to a difference in the levels of caveolin,
receptors and/or co-receptors), as observed in the current study, and
may explain the discrepancy. Here, we demonstrate that, in contrast
to other TGF-β co-receptors, CD109 may regulate TGF-β receptor
internalization and degradation in a ligand-dependent manner.
Although the events downstream of TGF-β receptor internalization
are ligand-dependent [34,35], studies on TGF-β receptor endocytosis
have been unable to demonstrate an effect of ligand on TGF-β receptor
compartmentalization or trafﬁcking [13,36]. Our results reveal that
ligand may play a role in CD109's effect on TGF-β receptor compart-
mentalization. By sucrose gradient fractionation, we show that CD109
promotes localization of TGFBR1 into the caveolae, in the presence of
TGF-β. Our ﬁndings are in line with the results obtained for several
receptors, such as insulin, β2adrenergic and EGF receptors, that localize
into caveolae in a ligand-dependent manner [37–39]. Although the
molecular mechanisms involved in TGF-β receptor internalization are
less well understood than those of the receptors above, our study
provides evidence that ligand addition can modulate TGF-β receptor
localization into caveolae in the presence of CD109. These ﬁndings
implicate a link between ligand-induced TGF-β receptor
Fig. 7. CD109 accelerates TGFBR1 proteasomal degradation. (A–B) Afﬁnity labeling: (A) 293 cells transfected with CD109 or EV and TGFBR1/TGFBR2 were afﬁnity labeled at 4 °C with
125
I-TGF-β, which was then covalently cross-linked to the receptors, and incubated at 37 °C for 0 to 8 h to allow receptor internalization. Left panel: The labeled receptors were
visualized by autoradiography. Coomassie blue staining shows equal protein loading. Right panel: The amount of labeled TGFBR1 was quantiﬁed by densitometry (mean of n=4
independent experiments±SEM, * difference between EV and CD109 groups is statistically signiﬁcant: pb0.05). (B) HaCaT cells stably transfected with CD109 (clone CD3-3) or EV
(clone EV3-3) were afﬁnity labeled as in (A), in the presence or absence of 20 μM MG132. Left panel: Labeled TGFBR1 and TGFBR2 were visualized by autoradiography. Coomassie
blue staining shows equal protein loading.Middle panel: The amount of labeled TGFBR1 was quantiﬁed by densitometry (mean of n=3 independent experiments±SEM, *: pb0.05).
Right panel: Western blot showing CD109 overexpression in CD3-3 clone, compared to EV3-3 clone. (C) Western blot: HaCaT cells transfected with control or CD109 siRNA were
treated with 100 pM TGF-β for 16 h, in the presence or absence of MG132 or chloroquine. Cell lysates were analyzed by western blot using the indicated antibodies (left panel). Right
panel: Densitometry of TGFBR1 (mean of n=3 independent experiments, ± SEM, *: pb0.05).
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dation. Our results demonstrating that CD109 facilitates TGF-β receptor
degradation is consistent with CD109's ability to direct TGF-β receptor
localization into the caveolae. Although TGF-β receptors have been
shown to be degraded by both lysosomal and proteasomal machineries
following receptor ubiquitination [35,40], limited data are available
on factors controlling TGFBR1 proteasomal degradation. Our results
showing that CD109 enhancement of TGFBR1 degradation is blocked by
the proteasome inhibitor MG132 but not by the lysosome inhibitor
chloroquine, suggest that CD109 may regulate TGFBR1 proteasomal
degradation.
An important ﬁnding in the present study is that CD109 inhibits
SMAD3 phosphorylation in a caveolin-dependent manner. One poten-
tial explanation is that CD109, bypromoting TGF-β receptor endocytosisinto the caveolae, sequesters the receptors away from SMAD2/3.
Furthermore, CD109 promotes TGF-β receptor degradation, which in
turn can lead to inhibition of signaling. CD109 may thus dampen TGF-β
responses in order to avoid a deleterious effect of excess TGF-β that
often leads to many human diseases such as tissue ﬁbrosis and cancer
metastasis. Because deregulation of CD109 expression may result in
aberrant TGF-β receptor internalization and degradation, CD109 may
represent a novel therapeutic target for treatment of diseases in which
TGF-β is known to play a pathophysiological role.
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Fig. 8. Schematicmodel of the potentialmechanism bywhich CD109may regulate TGF-β receptor internalization and degradation. TGF-β receptors can internalize via the clathrin-coated
pits or the caveolar pathway [13]. CD109 increases TGF-β binding to TGF-β receptors and promotes TGF-β receptor localization to the caveolae, thereby facilitating TGF-β receptor
endocytosis via the caveolar pathway and/or enhancing proteasomal degradation of TGFBR1. These effects of CD109 ultimately lead to downregulation of TGF-β signaling.
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